Skip to main content

Environmental Exposure

3
Pipeline Programs
3
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
3 programs
3
[14C]-benzo[a]pyrenePhase 11 trial
[14C]-benzo[a]pyrenePhase 11 trial
[14C]-benzo[a]pyrenePhase 11 trial
Active Trials
NCT03318978Completed8Est. Feb 2024
NCT03631667Completed8Est. Feb 2024
NCT03802721Completed7Est. Feb 2024
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
InterventionN/A2 trials
Active Trials
NCT05258656Active Not Recruiting1,800Est. Jan 2029
NCT01244568Completed218Est. Jan 2013
Marker Therapeutics
1 program
Urinary EDC metabolite testingN/A2 trials
Active Trials
NCT07560579Active Not Recruiting226Est. Sep 2026
NCT06450951Active Not Recruiting600Est. May 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Oregon Therapeutics[14C]-benzo[a]pyrene
Oregon Therapeutics[14C]-benzo[a]pyrene
Oregon Therapeutics[14C]-benzo[a]pyrene
Marker TherapeuticsUrinary EDC metabolite testing
Marker TherapeuticsUrinary EDC metabolite testing
Allergy TherapeuticsIntervention
Allergy TherapeuticsIntervention

Clinical Trials (7)

Total enrollment: 2,867 patients across 7 trials

NCT03802721Oregon Therapeutics[14C]-benzo[a]pyrene

Pharmacokinetics of Benzo[a]Pyrene: Impact of Diet

Start: Jan 2019Est. completion: Feb 20247 patients
Phase 1Completed
NCT03631667Oregon Therapeutics[14C]-benzo[a]pyrene

Ultralow Dose PAH Binary Mixture Study

Start: Oct 2018Est. completion: Feb 20248 patients
Phase 1Completed
NCT03318978Oregon Therapeutics[14C]-benzo[a]pyrene

Benzo[a]Pyrene Ultralow Dose-Response Study

Start: Apr 2018Est. completion: Feb 20248 patients
Phase 1Completed
NCT07560579Marker TherapeuticsUrinary EDC metabolite testing

Weight Loss and Endocrine Disrupting Chemicals (EDCs): Lifestyle Interventions to Lose Weight and Reduce EDC Exposure in Individuals With Overweight/Obesity

Start: Aug 2025Est. completion: Sep 2026226 patients
N/AActive Not Recruiting
NCT06450951Marker TherapeuticsUrinary EDC metabolite testing

A Personalized Biomonitoring and Report-back Intervention to Reduce Exposure to Endocrine Disrupting Chemicals

Start: May 2024Est. completion: May 2026600 patients
N/AActive Not Recruiting

Childhood Activities Nutrition and Development Oversight

Start: Mar 2022Est. completion: Jan 20291,800 patients
N/AActive Not Recruiting

Decision Support Interventions (DESI) for Prostate Cancer Screening and Treatment - Study 2

Start: Dec 2010Est. completion: Jan 2013218 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Environmental Exposure | Pipeline & Competitive Landscape | Formulate